The Motley Fool
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.
Fri Jul 25, 2014
Customer Interaction Solutions
European CHMP Adopts Positive Opinion for Gilead's Zydelig...
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorization Application for Zydelig , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular ... (more)
Thu Jul 24, 2014
STTG Market Recap July 23, 2014
Indexes were up most of the session as a surge by Apple helped lift things; this is a massive component of the NASDAQ.
Gilead Sciences (GILD) Releases Quarterly Earnings, Beats Estimates By $0.63 EPS
Gilead Sciences released its earnings data on Wednesday. The company reported $2.36 earnings per share for the quarter, beating the analysts' consensus estimate of $1.73 by $0.63, American Banking News.com reports.
Wed Jul 23, 2014
Customer Interaction Solutions
Gilead Announces New Agreement with Medicines Patent Pool for Access...
Gilead Sciences, Inc. announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead's investigational drug tenofovir alafenamide for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.
U.S. FDA Approves Gilead Sciences, Inc.'s Zydelig (idelalisib)...
U.S. FDA Approves Gilead Sciences, Inc. 's Zydelig For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma U.S. FDA Approves FDA's ZydeligA For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma 82 Percent Reduction in Risk of Disease Progression or Death When Combined ... (more)
Gilead Sciences Announces Second Quarter 2014 Financial Results
Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2014.
Will controversial hepatitis C drug continue its blockbuster sales?
Gilead Sciences' $1,000-a-day hepatitis C pill is facing a firestorm of criticism from insurers and lawmakers, but none of those obstacles are likely to stop the Foster City company from reporting blockbuster revenues during the second quarter today.
Tue Jul 22, 2014
Netflix falls on lower quarterly forecast
That's how much Netflix shares dropped on Tuesday after the streaming-video company forecast a profit of 89 cents a share, falling short of the $1.02 projected by analysts.
Mon Jul 21, 2014
Costly hepatitis C drugs could add $300 to every American's yearly premium, CVS says
Gilead Sciences' new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks.
Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?
Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed.
Thu Jul 17, 2014
Could California spend $6.7 billion for hepatitis C drug?
This undated handout photo provided by Gilead Sciences shows the Hepatitis-C medication Sovaldi.
Wed Jul 16, 2014
Investor's Business Daily
Gilead Sciences to Release Second Quarter 2014 Financial Results on...
Gilead Sciences, Inc. announced today that its second quarter 2014 financial results will be released on Wednesday, July 23, at 4:05 p.m. Eastern Time.
Fri Jul 11, 2014
Inside Bay Area
U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug
Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000, raising renewed concerns over the high costs to taxpayers.
Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners
July 11, 2014 The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall.
Thu Jul 10, 2014
A Pre-Earnings Update On Gilead
Background : Gilead Sciences may remain substantially undervalued relative to the market despite its tremendous stock price appreciation recently and over many years.
Wed Jul 09, 2014
Gilead Sciences Moves Up In Market Cap Rank, Passing PepsiCo
Market capitalization is an important data point for investors to keep an eye on, for various reasons.
Wed Jul 02, 2014
Strong IPO Market for Life Sciences Companies Defines First Half of 2014
Life sciences companies raised $4.7 billion globally in 68 initial public offerings during the first half 2014, exceeding the 66 life sciences IPOs completed in all of 2013.
Mon Jun 30, 2014
Wall St. Cheat Sheet
Why Gilead Sciences Is a Must-Own Stock
Gilead Sciences Inc . is one of my top choices for any stocks moving forward through 2014 into 2015.